Cite
HARVARD Citation
Conaghan, P. et al. (2023). Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet. pp. e263-e273. [Online].